» Articles » PMID: 30691681

Regulation of Cancer Stem Cell Properties by SIX1, a Member of the PAX-SIX-EYA-DACH Network

Overview
Journal Adv Cancer Res
Publisher Elsevier
Specialty Oncology
Date 2019 Jan 30
PMID 30691681
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The PAX-SIX-EYA-DACH network (PSEDN) is a central developmental transcriptional regulatory network from Drosophila to humans. The PSEDN is comprised of four conserved protein families; including paired box (PAX), sine oculis (SIX), eyes absent (EYA), and dachshund (DACH). Aberrant expression of PSEDN members, particularly SIX1, has been observed in multiple human cancers, where SIX1 expression correlates with increased aggressiveness and poor prognosis. In conjunction with its transcriptional activator EYA, the SIX1 transcription factor increases cancer stem cell (CSC) numbers and induces epithelial-mesenchymal transition (EMT). SIX1 promotes multiple hallmarks and enabling characteristics of cancer via regulation of cell proliferation, senescence, apoptosis, genome stability, and energy metabolism. SIX1 also influences the tumor microenvironment, enhancing recruitment of tumor-associated macrophages and stimulating angiogenesis, to promote tumor development and progression. EYA proteins are multifunctional, possessing a transcriptional activation domain and tyrosine phosphatase activity, that each contributes to cancer stem cell properties. DACH proteins function as tumor suppressors in solid cancers, opposing the actions of SIX-EYA and reducing CSC prevalence. Multiple mechanisms can lead to increased SIX1 expression, including loss of SIX1-targeting tumor suppressor microRNAs (miRs), whose expression correlates inversely with SIX1 expression in cancer patient samples. In this review, we discuss the major mechanisms by which SIX1 confers CSC and EMT features and other important cancer cell characteristics. The roles of EYA and DACH in CSCs and cancer progression are briefly highlighted. Finally, we summarize the clinical significance of SIX1 in cancer to emphasize the potential therapeutic benefits of effective strategies to disrupt PSEDN protein interactions and functions.

Citing Articles

All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.

Hughes C, Alderman C, Wolin A, Fields K, Zhao R, Ford H Biochim Biophys Acta Rev Cancer. 2024; 1879(3):189098.

PMID: 38555001 PMC: 11111358. DOI: 10.1016/j.bbcan.2024.189098.


SIX1 amplification modulates stemness and tumorigenesis in breast cancer.

Guo L, Li F, Liu H, Kong D, Chen C, Sun S J Transl Med. 2023; 21(1):866.

PMID: 38031089 PMC: 10685563. DOI: 10.1186/s12967-023-04679-2.


SIX1 Downregulation Suppresses Self-renewal Capacity and THY1 Expression in Hepatocellular Carcinoma and SIX1 Dominate the Survival in Liver Cancer.

Balcik-Ercin P, Aysan A, Salik N, Erciyas E Turk J Gastroenterol. 2023; 34(8):881-889.

PMID: 37427884 PMC: 10544153. DOI: 10.5152/tjg.2023.22293.


Transcriptomic analysis reveals the role of SIX1 in mouse cranial neural crest patterning and bone development.

Baxi A, Jourdeuil K, Cox T, Clouthier D, Tavares A Dev Dyn. 2023; 252(10):1303-1315.

PMID: 37183792 PMC: 10592572. DOI: 10.1002/dvdy.597.


Retinal determination gene networks: from biological functions to therapeutic strategies.

Zhu S, Li W, Zhang H, Yan Y, Mei Q, Wu K Biomark Res. 2023; 11(1):18.

PMID: 36750914 PMC: 9906957. DOI: 10.1186/s40364-023-00459-8.